GMED Stock Risk & Deep Value Analysis

Globus Medical Inc

DVR Score

8.9

out of 10

Hidden Gem

The Bottom Line on GMED

We analyzed Globus Medical Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran GMED through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Mar 22, 2026•Run Fresh Analysis →•

Get notified when GMED moves

Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.

📈GMED Performance Overview3yr weekly

📊

Unlock GMED Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

GMED Stock Risk Analysis

Overall Risk

Moderate

Financial Risk

Low

Market Risk

Low

GMED Deep Value Analysis

Globus Medical Inc (GMED) demonstrates strong execution and significant upside potential following its strategic merger with NuVasive. The Q4 2025 earnings report was exceptionally strong, with beats on both revenue and EPS, showcasing robust YoY growth (+25.7% revenue, +52.1% EPS) and confirming that the integration is exceeding synergy targets. Free cash flow surged by 150% to $588.8M, highlighting a solid financial foundation. The company's leadership in robotic surgery (ExcelsiusGPS) and expanded market presence in spine/ortho segments create a durable competitive moat and clear avenues for substantial market share gains. While insider sales are noted, the overwhelming institutional ownership (95.16%) and analyst upgrades affirm strong conviction. GMED is well-positioned for future market leadership and 10x growth within the 3-5 year horizon.

GMED Research Sources

Research sources

No external source links for this analysis yet. Run a fresh analysis to capture SEC filings and financial news articles we used.

For educational context only. Not financial advice.

GMED Red Flags & Warning Signs

⚠
Unexpected regulatory hurdles for new medical devices
⚠
Increased competitive pressure from major players (e.g., Medtronic, Stryker)
⚠
Slower-than-expected integration of NuVasive/Nevro operations

Unlock GMED Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

GMED Financial Health Metrics

Market Cap

$12.77B

P/E Ratio

24.21

Profit Margin

18.30%

Debt-to-Equity

0.00

Dividend Yield

0.00%

Beta (Volatility)

1.06

Earnings Per Share

$1.28

GMED Competitive Moat Analysis

Moat Rating

Narrow

Moat Trend

Expanding

Moat Sources

3 Identified

Intangible Assets/IP (proprietary robotic technology, patents)Switching Costs (surgeon training, integration into hospital systems, product ecosystem)Efficient Scale (post-merger market leadership and cost advantages)

The moat is strengthening due to the successful integration of NuVasive, which enhances product breadth and market reach. High switching costs for surgeons trained on ExcelsiusGPS and hospitals invested in the system create durable customer loyalty. Strong IP in robotic surgery further reinforces its position.

GMED Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

GMED Catalysts & Growth Drivers

Near-Term (0-6 months)

•Q1 2026 Earnings (Estimated late April/early May 2026)
•Further updates on NuVasive/Nevro synergy realization
•Potential new product or feature announcements for ExcelsiusGPS

Medium-Term (6-18 months)

•Expanded international market penetration for merged product portfolio
•Strategic partnerships to accelerate robotic surgery adoption
•Increased market share gains in core spine and orthopedic segments

Long-Term (18+ months)

•Establishment as a dominant global leader in orthopedic robotics and surgical solutions
•Disruption of traditional surgical methods through advanced navigation and AI
•Expansion into new high-growth musculoskeletal sub-segments

Catalysts & Growth Drivers

GMED Bull Case: What Could Go Right

✓
Sustained organic revenue growth above 10% YoY in base business
✓
Continued improvement or stability in adjusted gross and EBITDA margins
✓
Successful launch and adoption rates of new robotic and implant technologies

Bull Case Analysis

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Globus Medical Inc (GMED)?

As of March 22, 2026, Globus Medical Inc has a DVR Score of 8.9 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Globus Medical Inc?

Globus Medical Inc's market capitalization is approximately $12.8B..

What is the risk level for GMED stock?

Our analysis rates Globus Medical Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of GMED?

Globus Medical Inc currently has a price-to-earnings (P/E) ratio of 24.2. This is in line with broader market averages.

Is Globus Medical Inc's revenue growing?

Globus Medical Inc has reported revenue growth of 25.7%. The company is showing strong top-line momentum.

Is GMED stock profitable?

Globus Medical Inc has a profit margin of 18.3%. The company is profitable but margins are modest.

How often is the GMED DVR analysis updated?

Our AI-powered analysis of Globus Medical Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 22, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.